89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints

Mar 22

Brad Good is a Circle Platinum Squarespace expert and Authorized Trainer who has built on the platform since 2008, with more than 1,900 sites to his name. He makes Language Switch, a multilingual plugin for Squarespace 7.1, and writes the guides on this site.

http://www.bradgood.net

89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints

89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock

Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights